Bioz and SOPHiA GENETICS Partner to Enhance Scientific Transparency with Custom Integration
PorAinvest
martes, 15 de julio de 2025, 4:16 am ET1 min de lectura
SOPH--
The partnership centers around the SOPHiA DDM Platform, which analyzes complex genomic and multimodal data to generate real-time, actionable insights for a broad network of hospital, laboratory, and biopharma institutions. Bioz has developed custom-designed features to complement the platform's capabilities, including Bioz Pro Badges and a Bioz Content Hub.
Bioz Pro Badges display peer-reviewed publications referencing the SOPHiA DDM Platform and Alamut Visual Plus, sorted by application. This allows users to easily explore clinical use cases relevant to their research. Additionally, the Bioz Content Hub offers a comprehensive and fully searchable interface for browsing scientific publications. Users can filter results by application, number of citations, journal author location, impact factor, and date, providing a research-driven experience that mirrors how scientists seek out trusted validation.
One of the key features of this integration is a customized citation count graph that visually displays the momentum of published studies over time. This graph, housed on the SOPHiA GENETICS Publications Page, helps users quickly grasp the growing scientific support behind the SOPHiA DDM Platform.
Mallory Gough, Senior Scientific Communication Manager at SOPHiA GENETICS, highlighted the benefits of the partnership, stating, "Bioz has transformed the way we showcase the real-world impact of our technology. The automation behind collecting and presenting peer-reviewed references has saved us countless hours, and the custom publication graph is a beautifully clear way to highlight the evidence backing our platform."
Dr. Karin Lachmi, co-founder and Chief Revenue Officer at Bioz, emphasized the importance of transparency and data-driven decision-making. "SOPHiA GENETICS' implementation of both Bioz Badges and a fully customized Content Hub demonstrates how companies can use scientific evidence not only to support product credibility but to make that credibility easily accessible and visually engaging."
With Bioz technology integrated into the SOPHiA GENETICS website, researchers and clinicians gain streamlined access to data-driven insights, enhancing transparency and evidence-based decision-making.
References:
[1] https://www.finanznachrichten.de/nachrichten-2025-07/65906035-bioz-inc-turning-proof-into-power-bioz-partners-with-sophia-genetics-to-enhance-scientific-transparency-via-custom-integration-200.htm
[2] https://www.nasdaq.com/articles/procept-biorobotics-announces-category-i-cpt-code-assignment-aquablation-therapy-effective
Bioz, an AI-powered solution, has partnered with SOPHiA GENETICS to enhance scientific transparency. The partnership focuses on SOPHiA GENETICS' SOPHiA DDM Platform, which now features Bioz Pro Badges and a custom-designed Bioz Content Hub. These features display peer-reviewed publications and provide a comprehensive search interface, allowing users to explore clinical use cases and browse scientific publications. The partnership aims to make scientific evidence easily accessible and visually engaging for users.
Bioz, Inc., an AI-powered solution revolutionizing scientific product evidence, has announced a strategic partnership with SOPHiA GENETICS, a leading cloud-native healthcare technology company. The collaboration aims to enhance scientific transparency and credibility by integrating Bioz's advanced tools into SOPHiA GENETICS' SOPHiA DDM Platform.The partnership centers around the SOPHiA DDM Platform, which analyzes complex genomic and multimodal data to generate real-time, actionable insights for a broad network of hospital, laboratory, and biopharma institutions. Bioz has developed custom-designed features to complement the platform's capabilities, including Bioz Pro Badges and a Bioz Content Hub.
Bioz Pro Badges display peer-reviewed publications referencing the SOPHiA DDM Platform and Alamut Visual Plus, sorted by application. This allows users to easily explore clinical use cases relevant to their research. Additionally, the Bioz Content Hub offers a comprehensive and fully searchable interface for browsing scientific publications. Users can filter results by application, number of citations, journal author location, impact factor, and date, providing a research-driven experience that mirrors how scientists seek out trusted validation.
One of the key features of this integration is a customized citation count graph that visually displays the momentum of published studies over time. This graph, housed on the SOPHiA GENETICS Publications Page, helps users quickly grasp the growing scientific support behind the SOPHiA DDM Platform.
Mallory Gough, Senior Scientific Communication Manager at SOPHiA GENETICS, highlighted the benefits of the partnership, stating, "Bioz has transformed the way we showcase the real-world impact of our technology. The automation behind collecting and presenting peer-reviewed references has saved us countless hours, and the custom publication graph is a beautifully clear way to highlight the evidence backing our platform."
Dr. Karin Lachmi, co-founder and Chief Revenue Officer at Bioz, emphasized the importance of transparency and data-driven decision-making. "SOPHiA GENETICS' implementation of both Bioz Badges and a fully customized Content Hub demonstrates how companies can use scientific evidence not only to support product credibility but to make that credibility easily accessible and visually engaging."
With Bioz technology integrated into the SOPHiA GENETICS website, researchers and clinicians gain streamlined access to data-driven insights, enhancing transparency and evidence-based decision-making.
References:
[1] https://www.finanznachrichten.de/nachrichten-2025-07/65906035-bioz-inc-turning-proof-into-power-bioz-partners-with-sophia-genetics-to-enhance-scientific-transparency-via-custom-integration-200.htm
[2] https://www.nasdaq.com/articles/procept-biorobotics-announces-category-i-cpt-code-assignment-aquablation-therapy-effective

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios